Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives
Xiangyu Huo,Duoduo Hou,Haixia Wang,Bin He,Jieyu Fang,Yao Meng,Luyang Liu,Zhanyong Wei,Zhenya Wang,Feng-Wu Liu
DOI: https://doi.org/10.1016/j.ejmech.2021.113684
IF: 7.088
2021-11-01
European Journal of Medicinal Chemistry
Abstract:<p>Respiratory syncytial virus (RSV) causes serious lower respiratory tract infections. Currently, the only clinical anti-RSV drug is ribavirin, but ribavirin has serious toxic side effect and can only be used by critically ill patients. A series of benzimidazole derivatives were synthesized starting from 1,4:3,6-dianhydro-<span class="small-caps">d</span>-fructose and a variety of <em>o</em>-phenylenediamines. Evaluation of their antiviral activity showed that compound <strong>a27</strong> had the highest antiviral activity with a half maximal effective concentration (EC<sub>50</sub>) of 9.49 μM. Investigation of the antiviral mechanism of compound <strong>a27</strong> indicated that it can inhibit the replication of RSV by inhibiting apoptosis and autophagy pathways. Retinoic acid-inducible gene (RIG)-I, TNF receptor associated factor (TRAF)-3, TANK binding kinase (TBK)-1, interferon regulatory factor (IRF)-3, nuclear factor Kappa-B (NF-κB), interferon (IFN)-β, Toll-like receptor (TLR)-3, interleukin (IL)-6 were suppressed at the cellular level. Mouse lung tissue was subjected to hematoxylin and eosin (HE) staining and immunohistochemistry, which showed that RSV antigen and M gene expression could be reduced by compound <strong>a27</strong>. Decreased expression of RIG-I, IRF-3, IFN-β, TLR-3, IL-6, interleukin (IL)-8, interleukin (IL)-10, inducible nitric oxide synthase (iNOS) and tumor necrosis factor (TNF)-α was also found <em>in vivo</em>.</p>
chemistry, medicinal